Edwards Lifesciences Research and development accruals increased by 0.9% to $69.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.8%, from $74.90M to $69.80M. Over 5 years (FY 2020 to FY 2025), Research and development accruals shows an upward trend with a 5.8% CAGR.
other_research_and_development_accruals| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $62.00M | $64.80M | $58.20M | $56.50M | $57.00M | $71.60M | $66.90M | $67.70M | $70.70M | $70.10M | $74.10M | $75.70M | $78.00M | $79.00M | $74.10M | $74.90M | $74.40M | $75.30M | $69.20M | $69.80M |
| QoQ Change | — | +4.5% | -10.2% | -2.9% | +0.9% | +25.6% | -6.6% | +1.2% | +4.4% | -0.8% | +5.7% | +2.2% | +3.0% | +1.3% | -6.2% | +1.1% | -0.7% | +1.2% | -8.1% | +0.9% |
| YoY Change | — | — | — | — | -8.1% | +10.5% | +14.9% | +19.8% | +24.0% | -2.1% | +10.8% | +11.8% | +10.3% | +12.7% | +0.0% | -1.1% | -4.6% | -4.7% | -6.6% | -6.8% |